Rome – 22 November 2022 – Angelini Industries announces the appointment of Jacopo Andreose as new Chief Executive Officer of Angelini Pharma, a pharmaceutical company active in brain health, including mental health and epilepsy, and consumer healthcare, which is part of the Angelini Industries, an Italian multi-business group.
Jacopo Andreose, who will take on the role from February 6, has over twenty years of experience in top management positions in the pharmaceutical industry: he arrives from Gilead Sciences – where he was Senior Vice President, Intercontinental Region, with direct responsibility for the business in Asia, Latin America, Middle East, Africa, Eastern Europe – having previously worked for GlaxoSmithKline/ViiV Healthcare, Bristol-Myers Squibb and Abbott, covering strategic and operational roles in Italy, the US, Europe and Asia.
“We are delighted to welcome Jacopo Andreose, who we have chosen for his extensive international experience and in-depth knowledge of the sector” – said Sergio Marullo di Condojanni and Thea Paola Angelini, respectively CEO and Executive Vice President of Angelini Industries – “We are confident that Jacopo will make a significant contribution to the development and growth path of Angelini Pharma, which for over a century has prioritized the health and care of people”.
“I am excited to have the opportunity to become part of Angelini Pharma, a company that combines tradition and the long-standing loyalty of patients and health workers in Italy and abroad with a strong focus on innovation” - said Jacopo Andreose - “I want to thank Sergio and Thea for their trust and that I can count on the support of the team as we continue our mission of offering patients, and their loved ones, innovative solutions for improving their health and their quality of life.
Angelini Pharma is part of Angelini Industries, an Italian multi-business group present in 21 countries in the healthcare, FMCG, industrial technology, perfumery and dermocosmetics, and wine sectors, with a turnover of €1.725 billion and 5,800 employees, over 4,000 of which in Italy.
Angelini Pharma is active in the pharmaceutical sector, where its primary focus is brain health, which includes mental health and epilepsy, and consumer healthcare. It operates in 20 countries and employs around 3,000 people.